Literature DB >> 19584001

Role of nitric oxide in obsessive-compulsive behavior and its involvement in the anti-compulsive effect of paroxetine in mice.

S N Umathe1, P S Bhutada, N S Jain, Y R Mundhada, S S Borkar, B Dhumal.   

Abstract

In view of the reports that nitric oxide modulates the neurotransmitters implicated in obsessive-compulsive disorder, patients with obsessive-compulsive disorder exhibit higher plasma nitrate levels, and drugs useful in obsessive-compulsive disorder influence nitric oxide, we hypothesized that nitric oxide may have some role in obsessive-compulsive behavior. We used marble-burying behavior of mice as the animal model of obsessive-compulsive disorder, and nitric oxide levels in brain homogenate were measured using amperometric nitric oxide-selective sensor method. Intraperitoneal administration of nitric oxide enhancers viz. nitric oxide precursor-l-arginine (800 mg/kg), nitric oxide donor-sodium nitroprusside (3 mg/kg) or phosphodiesterase type 5 inhibitor-sildenafil (3 mg/kg) significantly increased marble-burying behavior as well as brain nitrites levels, whereas treatment with 7-nitroindazole-neuronal nitric oxide synthase inhibitor (20-40 mg/kg, i.p.) or paroxetine-selective serotonin reuptake inhibitor (5-10 mg/kg, i.p.) dose dependently attenuated marble-burying behavior and nitrites levels in brain. Further, co-administration of sub-effective doses of 7-nitroindazole (10 mg/kg) and paroxetine (2.5 mg/kg) significantly attenuated marble-burying behavior. Moreover, pretreatment with l-arginine (400 mg/kg, i.p.), sodium nitroprusside (2.0 mg/kg, i.p.) or sildenafil (2.0 mg/kg, i.p.) significantly attenuated the inhibitory influence of 7-nitroindazole (40 mg/kg) or paroxetine (10 mg/kg) on marble-burying behavior as well as on brain nitrites levels. None of the above treatment had any significant influence on locomotor activity. In conclusion, obsessive compulsive behavior in mice appears related to nitric oxide in brain, and anti-compulsive effect of paroxetine appears to be related to decrease central levels of nitric oxide.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584001     DOI: 10.1016/j.niox.2009.07.001

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  8 in total

1.  Role of nitric oxide in amphetamine-induced sensitization of schedule-induced polydipsic rats.

Authors:  Yia-Ping Liu; Che-Se Tung; Pai-Jone Lin; Fang-Jung Wan
Journal:  Psychopharmacology (Berl)       Date:  2011-05-28       Impact factor: 4.530

2.  Changes of Nitric Oxide and Peroxynitrite Serum Levels during Drug Therapy in Patients with Obsessive-Compulsive Disorder.

Authors:  Leila Kouti; Mehdi Sayyah; Parisa Mosallanezhad; Sara Kooti; Maryam Aghakoochakzadeh; Kaveh Eslami
Journal:  Adv Med       Date:  2016-10-16

Review 3.  The role of brain gaseous neurotransmitters in anxiety.

Authors:  Artur Pałasz; Itiana Castro Menezes; John J Worthington
Journal:  Pharmacol Rep       Date:  2021-03-13       Impact factor: 3.024

4.  Oxidative and Nitrosative Stress in Major Depressive Disorder: A Case Control Study.

Authors:  Aditya Somani; Abhishek Kumar Singh; Bandna Gupta; Sheela Nagarkoti; Pronob Kumar Dalal; Madhu Dikshit
Journal:  Brain Sci       Date:  2022-01-21

5.  Early-adolescent antibiotic exposure results in mitochondrial and behavioral deficits in adult male mice.

Authors:  Anouk C Tengeler; Tim L Emmerzaal; Bram Geenen; Vivienne Verweij; Miranda van Bodegom; Eva Morava; Amanda J Kiliaan; Tamas Kozicz
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

6.  Dentate nNOS accounts for stress-induced 5-HT1A receptor deficiency: Implication in anxiety behaviors.

Authors:  Li-Juan Zhu; Chu Xu; Jie Ren; Lei Chang; Xian-Hui Zhu; Nan Sun; Guo-Liang Meng; Meng-Ying Liu; Jing Zhang; Yuan-Yuan Li; Yu-Lin Tang; Qi-Gang Zhou
Journal:  CNS Neurosci Ther       Date:  2019-12-21       Impact factor: 5.243

Review 7.  Update on Statin Treatment in Patients with Neuropsychiatric Disorders.

Authors:  Razieh Avan; Adeleh Sahebnasagh; Javad Hashemi; Mahila Monajati; Fatemeh Faramarzi; Neil C Henney; Fabrizio Montecucco; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Life (Basel)       Date:  2021-12-08

8.  Smo-Shh Agonist Purmorphamine Prevents Neurobehavioral and Neurochemical Defects in 8-OH-DPAT-Induced Experimental Model of Obsessive-Compulsive Disorder.

Authors:  Ria Gupta; Sidharth Mehan; Pranshul Sethi; Aradhana Prajapati; Abdulrahman Alshammari; Metab Alharbi; Haneen A Al-Mazroua; Acharan S Narula
Journal:  Brain Sci       Date:  2022-03-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.